Enables protein kinase C binding activity. Involved in response to vitamin E. Located in interchromatin granule; nuclear speck; and perichromatin fibrils. Human ortholog(s) of this gene implicated in acute myeloid leukemia; congestive heart failure; hepatocellular carcinoma; and myelodysplastic syndrome. Orthologous to human SRSF2 (serine and arginine rich splicing factor 2); PARTICIPATES IN spliceosome pathway; INTERACTS WITH (R,R,R)-alpha-tocopherol; 2,3,7,8-tetrachlorodibenzodioxine; 2,4-dinitrotoluene.
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of SRSF2 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased expression of SRSF2 mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of SRSF2 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased expression of SRSF2 mRNA
[[Cisplatin results in increased expression of SRSF2 protein] which affects the splicing of CASP8 mRNA] which results in increased activity of CASP8 protein more ...
[Cuprizone co-treated with Clozapine] results in increased expression of SRSF2 protein and [Cuprizone co-treated with Haloperidol] results in increased expression of SRSF2 protein
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [KAT5 protein results in increased acetylation of and results in increased degradation of SRSF2 protein]
titanium dioxide results in decreased methylation of SRSF2 gene and titanium dioxide results in decreased methylation of SRSF2 promoter alternative form
Distribution of snRNPs, splicing factor SC-35 and actin in interphase nuclei: immunocytochemical evidence for differential distribution during changes in functional states.
Serine/arginine rich splicing factor 2 expression and clinic pathological features indicating a prognostic factor in human hepatocellular carcinoma patients.
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.